Author Archives: Julian Upton

Big Pharma’s Big Tuesday: A New Age of Megamerger?

What’s the opposite of Black Tuesday? White Tuesday? Bright Tuesday? Because Tuesday the stock market was buzzing following the news that Novartis is to acquire GSK’s cancer drugs business, while selling its vaccines division to GSK. With the speculation of a $100bn Pfizer bid for AstraZeneca and Valeant Pharmaceuticals added in, prices went soaring. As of […]
Posted in Deals, Europe, Global, Strategy | Tagged , , , , , | Leave a comment

BBC Takes Aim at GSK Corruption

GlaxoSmithKline’s legal wrangle concerning corrupt practices in Poland was one target of a pharma expose by the BBC’s flagship current affairs show Panorama this week.
Posted in compliance, Corporate Responsibility, Europe, Events, Global | Tagged , , , , , | Leave a comment

Six Steps to Better Cancer Care in Europe

A  report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.
Posted in Europe, healthcare | Tagged , , , | Leave a comment

Biotech Industry Calls for Pan-European Tax Incentives

Europe’s biotech industry body, EuropaBio, has launched a report urging European governments to remain committed to biotech research, development and innovation (RDI) incentives, following release of the European Commission’s (EC) 2014 Innovation Scoreboard.
Posted in Biotech, Europe, Global, R&D, Regulatory | Tagged , , , , , | Leave a comment

Innovation Drops Down NICE’s Value Agenda

Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions. Omar Ali, a UK formulary development pharmacist and consultant to NICE, speaking at eyeforpharma’s Barcelona 2014 conference on Wednesday, explained that the UK price watchdog will prioritize considerations of wider societal benefit and unmet need as it […]
Posted in Europe, Events, pricing | Tagged , , , , , | Leave a comment
  • Categories

  • Meta